Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

The effects of l-Carnosine on development of metabolic syndrome in rats.

Al-Sawalha NA, Alshogran OY, Awawdeh MS, Almomani BA.

Life Sci. 2019 Nov 15;237:116905. doi: 10.1016/j.lfs.2019.116905. Epub 2019 Oct 11.

PMID:
31610198
2.

The quality of consent form structure in biomedical research: a study from Jordan and Sudan.

Ibrahim MA, Alshogran OY, Khabour OF, Alzoubi KH.

J Multidiscip Healthc. 2019 Sep 2;12:727-731. doi: 10.2147/JMDH.S219316. eCollection 2019.

3.

Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition.

Alshogran OY.

Curr Drug Metab. 2019;20(8):633-645. doi: 10.2174/1389200220666190701095807.

PMID:
31267868
4.

Nosocomial Infections among Patients with Intracranial Hemorrhage: A Retrospective Data Analysis of Predictors and Outcomes.

Jaradat RW, Lahlouh AB, Alshogran OY, Aldabbour BA, Balusha AA.

Clin Neurol Neurosurg. 2019 Jul;182:158-166. doi: 10.1016/j.clineuro.2019.05.016. Epub 2019 May 20.

PMID:
31151044
5.

Investigating the Contribution of NPSR1, IL-6 and BDNF Polymorphisms to Depressive and Anxiety Symptoms in Hemodialysis Patients.

Alshogran OY, Al-Eitan LN, Altawalbeh SM, Khalil AA, Alqudah MAY, Oweis AO, Aman HA, Alhawari HH.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109657. doi: 10.1016/j.pnpbp.2019.109657. Epub 2019 May 25.

PMID:
31132388
6.

Factors affecting hypertensive patients' compliance with healthy lifestyle.

Alefan Q, Huwari D, Alshogran OY, Jarrah MI.

Patient Prefer Adherence. 2019 Apr 23;13:577-585. doi: 10.2147/PPA.S198446. eCollection 2019.

7.

Overactive bladder and associated psychological symptoms: A possible link to vitamin D and calcium.

Abdul-Razzak KK, Alshogran OY, Altawalbeh SM, Al-Ghalayini IF, Al-Ghazo MA, Alazab RS, Halalsheh OM, Sahawneh FE.

Neurourol Urodyn. 2019 Apr;38(4):1160-1167. doi: 10.1002/nau.23975. Epub 2019 Mar 14.

PMID:
30869826
8.

Evaluation of the impact of waterpipe tobacco smoke exposure on the activity and expression of rat hepatic CYP450: a pharmacokinetic study.

Alshogran OY, Magarbeh LS, Alzoubi KH, Saleh MI, Khabour OF.

Inhal Toxicol. 2018 Nov - Dec;30(13-14):519-526. doi: 10.1080/08958378.2019.1569182. Epub 2019 Feb 8.

PMID:
30734611
9.

Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.

Altawalbeh SM, Alshogran OY, Smith KJ.

Value Health. 2018 Dec;21(12):1365-1372. doi: 10.1016/j.jval.2018.06.009. Epub 2018 Jul 24.

10.

Patterns of self-medication among medical and nonmedical University students in Jordan.

Alshogran OY, Alzoubi KH, Khabour OF, Farah S.

Risk Manag Healthc Policy. 2018 Sep 12;11:169-176. doi: 10.2147/RMHP.S170181. eCollection 2018.

11.

Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits.

Alzoubi KH, Ismail ZB, Al-Essa MK, Alshogran OY, Abutayeh RF, Abu-Baker N.

Clin Pharmacol. 2018 Jun 12;10:73-78. doi: 10.2147/CPAA.S167150. eCollection 2018.

12.

Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients.

Alshogran OY, Khalil AA, Oweis AO, Altawalbeh SM, Alqudah MAY.

Gen Hosp Psychiatry. 2018 Jul - Aug;53:25-31. doi: 10.1016/j.genhosppsych.2018.04.003. Epub 2018 Apr 24.

PMID:
29727764
13.

Evaluation of the Effect of Uremic Serum on Hepatic Reductase Functional Expression.

Alshogran OY, Al-Obaidi EAF, Al-Husein BA, Oweis AO.

Drug Metab Lett. 2018;12(1):75-81. doi: 10.2174/1872312812666180416154436.

PMID:
29658443
14.

Understanding of International Committee of Medical Journal Editors Authorship Criteria Among Faculty Members of Pharmacy and Other Health Sciences in Jordan.

Alshogran OY, Al-Delaimy WK.

J Empir Res Hum Res Ethics. 2018 Jul;13(3):276-284. doi: 10.1177/1556264618764575. Epub 2018 Apr 9.

15.

Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes.

Alshogran OY.

Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1063-1073. doi: 10.1080/17425255.2017.1376648. Epub 2017 Sep 9. Review.

PMID:
28871815
16.

Implications of Kidney Disease on Metabolic Reduction.

Alshogran OY, Nolin TD.

Curr Drug Metab. 2016;17(7):663-72. Review.

PMID:
27262337
17.

Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

Alshogran OY, Ocque AJ, Leblond FA, Pichette V, Nolin TD.

J Chromatogr Sci. 2016 Apr;54(4):554-60. doi: 10.1093/chromsci/bmv186. Epub 2015 Dec 11.

18.

Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease.

Alshogran OY, Urquhart BL, Nolin TD.

Drug Metab Lett. 2015;9(2):111-8.

PMID:
26282591
19.

Effect of experimental kidney disease on the functional expression of hepatic reductases.

Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD.

Drug Metab Dispos. 2015 Jan;43(1):100-6. doi: 10.1124/dmd.114.061150. Epub 2014 Oct 20.

PMID:
25332430
20.

Determination of warfarin alcohols by ultra-high performance liquid chromatography-tandem mass spectrometry: application to in vitro enzyme kinetic studies.

Alshogran OY, Ocque AJ, Zhao J, Day BW, Leblond FA, Pichette V, Nolin TD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 1;944:63-8. doi: 10.1016/j.jchromb.2013.11.014. Epub 2013 Nov 14.

PMID:
24291722
21.

Multi-drug resistance 1 genetic polymorphism and prediction of chemotherapy response in Hodgkin's Lymphoma.

Mhaidat NM, Alshogran OY, Khabour OF, Alzoubi KH, Matalka II, Haddadin WJ, Mahasneh IO, Aldaher AN.

J Exp Clin Cancer Res. 2011 Jul 16;30:68. doi: 10.1186/1756-9966-30-68.

Supplemental Content

Loading ...
Support Center